Tag Archives: corporate VC

Hot Investor Mandate 4: Corporate Venture Arm of Global Pharma Seeks Therapeutics Companies with Focus on Pre-IND Assets in All Indications

21 Jun

A financially driven corporate life science venture fund of a global pharmaceutical company, invests with the purpose of fostering innovation, driving significant patient benefit, and generating superior returns by creating and investing in innovative life science companies at various stages of their development, independent from the corporate’s strategy. The firm has offices in USA and Europe, and focuses its investment activities in these countries. The firm typically makes equity investments in early venture rounds, investing up to $25 million over multiple financing rounds with 6-8 investments in any given year.

The firm invests in therapeutics with a focus on pre-IND assets and Series A investment rounds. The firm is interested in all classes and indications of innovative therapeutics with paradigm shifting potential.

The firm invests exclusively in privately held companies and aims to be a lead or co-lead with a director position.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Corporate Venture Arm of Leading Netherlands’ Telecom Service Provider Looking for Data and Software-Based Healthcare Technologies

19 Apr

Established in 2015, a corporate venture capital investment arm of a leading telecom and ICT service provider has interests in a variety of sectors in relation to their corporate activities, one of them being Digital Health. The firm manages a €70M revolving venture fund via which the firm invests in fast growing technology companies (Series A-C). In addition, the firm selectively invest in venture capital investment funds that complement the firm’ direct investment strategy and provide broader access to new technology companies and partnership opportunities. In January 2018, the firm for example initiated an early stage (seed) investment fund with multiple Dutch investors.

The firm aims to create value-creating partnerships with innovative technology companies providing access to capital, industry expertise, professional network and customer channels. The firm mainly focuses on opportunities based in Europe but is also interested to get in touch with companies which are located in USA and Canada, as long as they have an interest in expanding their commercial activities to the Netherlands. The firm’s initial ticket size typically ranges from €0.5M to €3M for minority stakes, building long-term partnerships, ultimately aiming for external exits, not acquisitions. The firm is open to both leading and co-investing, depending on the proposition. While the firm does not aim for a specific number of investments, the firm has made 6 investments per year since establishment.

The firm is highly interested in B2B/B2C software-based technology companies. The firm will only consider medical or diagnostic hardware companies that have a strong data or software component. The firm is especially interested in technologies that enable easier and smarter health management for patients and or medical professionals (i.e. self-monitoring devices for chronic disease management with real-time data accessibility, preventative healthcare, etc.). The firm is also interested in propositions that focus on (cyber) security solutions and or propositions that create efficiencies/cost-reductions within health organizations.

The firm seeks technologies that have a strategic fit or enough potential for a future collaboration with the firm’s health business, that fall under the firm’s sectors of interest. The firm prefers to work with management teams with a proven track record and wants to see market traction/validation, with at least €0.5M in annual revenues.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

RESI on MaRS Panel Announcement: Corporate Venture Capital

22 Mar

By Cole Bunn, Director of Research, LSN

cole-wp

Large corporations, especially in the pharmaceutical and biotech world, play a very important role in anchoring an innovation ecosystem. The most notable activity of these corporations is perhaps their role as an investor in and buyer of innovation – an exit partner. However, attracting and concentrating talent, and providing access to resources and experts are also vital elements of a healthy entrepreneurial community that big pharma brings with its presence. Corporate venture funds, which can serve as a vehicle for big pharma to make riskier/earlier investments, continue to find their way into more and more biotech venture rounds every year.

Toronto, looking to ramp up commercialization of its world-class research and put its name on the map as a life science powerhouse, will host the RESI conference for the third time as a part of the Toronto Health Innovation Week and welcome a panel of Corporate Venture investors. This increasingly important investor class will discuss trends in the space, their current interests, and how entrepreneurs can best prepare to pitch to and work with a group like theirs.

Moderated by Salim Teja, President, Venture Services, MaRS Discovery District, this panel will feature:

  • Marian Nakada, VP of Venture Investing, Johnson & Johnson
  • Jens Eckstein, President, SR One
  • Richard Osborn, Managing Partner, TELUS Ventures
  • Tom Gibbs, Director, Debiopharm Innovation Fund

By registering for RESI on MaRS, you’ll be able to listen to the Corporate Venture Capital panel live and learn how to position yourself to work with this type of group as well as interact with the a range of investors and entrepreneurs and experience numerous opportunities to expand your network in the life sciences.

%d bloggers like this: